Palvella Therapeutics, Inc.
$115.42
+10%Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -31.1).
Valuation inputs: P/E -31.1, earnings yield N/A, momentum +10.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.5%, ROIC -79.7%).
Profitability stack: net margin 0.0%, ROE -1.5%, ROIC -79.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +53.0%, momentum +10.3%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Palvella Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Palvella Therapeutics, Inc. Fair Value Envelope
Palvella Therapeutics, Inc. Profit Bridge
Profitability Analysis
Palvella Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Palvella Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Palvella Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that PVLA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 205.15, with estimates ranging from a low of 143.00 to a high of 255.00.
The consensus 1-year price target stands at 205.15, with estimates ranging from a low of 143.00 to a high of 255.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Palvella Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.47M and sold $1.66M worth of PVLA shares, resulting in $807K of net buying activity.
3 Months
445
49.97K
7.1K
826.92K
-777K
-$777K
3-6 Months
6.4K
800.00K
7.9K
707.36K
+93K
+$93K
6-9 Months
0
0.00
1.5K
128.58K
-129K
-$129K
9-12 Months
61.8K
1.62M
0
0.00
+1.6M
+$1.62M
Top Buyers
Jenkins George M
Director
$874K
Heron Elaine J
Director
$624K
Kiritsy Christopher P
Director
$324K
Wessel Tadd S.
Director
$324K
Davis Todd C
Director
$324K
Top Sellers
Goin Kathleen
Officer: Chief Operating Officer
$1.66M
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $807K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
No Dividend Yield Data
PVLA has not reported any dividend yield values in the available annual periods.
pvla Dividend History
Learning Layer
Related Guides
Build conviction on PVLA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.